Share Price, page-8877

He didn't say he's happy to not go it alone either. He merely said NEU has got the resources and experience to go it alone, but he wants to investigate all options to see which path gets to development and to patients quicker and also produces the best return for shareholders. One option could be to do the ph III trials ourselves, and if successful then licence out the marketing and distribution to a couple of big pharmas with resources in different regions. The royalties to us would likely be much higher since we've taken a lot of the risk out of the proposition.